News Quantified

ACIU – ac immune sa (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

AC Immune to Present at the Jefferies 2025 London Healthcare Conference

AC Immune (NASDAQ:ACIU) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $8.00 price target on the stock.

AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board

First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune’s ACI-19626 in Precision Medicine

4.4%

BEAT

15.6%

MISS

Form 6-K AC Immune SA For: Nov 04

Form 144 AC Immune SA Filed by: Pfeifer Andrea

Form 144 AC Immune SA Filed by: Pfeifer Andrea

Top News Gainers

11/13 AC Immune Q3 2019 Financial Results and Business Update 16.6%

3/30 Form 20-F AC Immune SA For: Dec 31 15.1%

3/23 Form 6-K AC Immune SA For: Mar 23 14.5%

6/11 AC Immune SA (NASDAQ: ACIU) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 11.2%

3/25 AC Immune SA (NASDAQ: ACIU) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. 9.4%

10/21 Massachusetts General Hospital First to Enroll Adults with Down Syndrome in New Nation-Wide Research Study Supported by LuMind IDSC Foundation 8.6%

4/2 AC Immune Presents the Latest Preclinical Data on Novel Drug Targets for Neurodegenerative Diseases 6.8%

11/19 AC Immune SA (NASDAQ: ACIU) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 5.8%

7/17 AC Immune Initiates Phase 1 Study of ACI-3024 Small Molecule Tau Morphomer™, an Investigational Treatment for Alzheimer’s Disease 5.6%

11/20 AC Immune SA (NASDAQ: ACIU) was upgraded by analysts at TheStreet from a "d" rating to a "c" rating. 4.7%

Top News Decliners

3/26 AC Immune SA (NASDAQ: ACIU) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. -30.1%

8/14 Form 6-K AC Immune SA For: Aug 14 -16.8%

3/14 AC Immune SA (NASDAQ: ACIU) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -9.0%

2/24 AC Immune SA (NASDAQ: ACIU) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.4%

4/27 AC Immune SA (NASDAQ: ACIU) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $8.75 price target on the stock. -7.0%

9/26 AC Immune SA (NASDAQ: ACIU) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -6.6%

6/28 Form 6-K AC Immune SA For: Jun 28 -6.1%

3/5 AC Immune SA (NASDAQ: ACIU) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $8.00 price target on the stock. -5.2%

8/12 AC Immune Announces Research Collaboration with University of Pennsylvania Focusing on Pathogenic Protein TDP-43 in Neurodegenerative Diseases -4.0%

2/10 AC Immune SA (NASDAQ: ACIU) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $11.00 price target on the stock. -3.8%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day